Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AKCA

Akcea Therapeutics (AKCA) Stock Price, News & Analysis

Akcea Therapeutics logo

About Akcea Therapeutics Stock (NASDAQ:AKCA)

Key Stats

Today's Range
$18.17
$18.17
50-Day Range
$18.13
$18.17
52-Week Range
$8.00
$21.70
Volume
N/A
Average Volume
361,806 shs
Market Capitalization
$1.85 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.

Receive AKCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akcea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKCA Stock News Headlines

Arcturus Therapeutics Holdings Inc ARCT
AKCA Historical Data
Buffett Dumps $982 Million in BofA Stock—What Does He Know?
Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.
Akcea Therapeutics Inc (AKCA)
See More Headlines

AKCA Stock Analysis - Frequently Asked Questions

Akcea Therapeutics, Inc. (NASDAQ:AKCA) released its quarterly earnings data on Tuesday, August, 4th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.14. The firm's revenue for the quarter was down 15.9% on a year-over-year basis.

Akcea Therapeutics (AKCA) raised $125 million in an initial public offering (IPO) on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities served as the underwriters for the IPO and BMO Capital Markets was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Advanced Micro Devices (AMD), Ciena (CIEN), Fossil Group (FOSL) and AMC Entertainment (AMC).

Company Calendar

Last Earnings
8/04/2020
Today
11/23/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AKCA
Fax
N/A
Employees
248
Year Founded
N/A

Profitability

Net Income
$40.77 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$488.54 million
Cash Flow
$0.51 per share
Book Value
$5.78 per share

Miscellaneous

Free Float
N/A
Market Cap
$1.85 billion
Optionable
Optionable
Beta
1.45
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:AKCA) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners